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Abstract
Background: Inhibition of parasite growth is a major objective of blood-stage malaria vaccines. The in vitro assay of parasite
growth inhibitory activity (GIA) is widely used as a surrogate marker for malaria vaccine efficacy in the down-selection of
candidate blood-stage vaccines. Here we report the first study to examine the relationship between in vivo Plasmodium
falciparum growth rates and in vitro GIA in humans experimentally infected with blood-stage malaria.
Methods: In this phase I/IIa open-label clinical trial five healthy malaria-naive volunteers were immunised with AMA1/C1-
Alhydrogel+CPG 7909, and together with three unvaccinated controls were challenged by intravenous inoculation of P.
falciparum infected erythrocytes.
Results: A significant correlation was observed between parasite multiplication rate in 48 hours (PMR) and both vaccine-
induced growth-inhibitory activity (Pearson r=20.93 [95% CI: 21.0, 20.27] P=0.02) and AMA1 antibody titres in the
vaccine group (Pearson r=20.93 [95% CI: 20.99, 20.25] P=0.02). However immunisation failed to reduce overall mean
PMR in the vaccine group in comparison to the controls (vaccinee 16 fold [95% CI: 12, 22], control 17 fold [CI: 0, 65] P=0.70).
Therefore no impact on pre-patent period was observed (vaccine group median 8.5 days [range 7.5–9], control group
median 9 days [range 7–9]).
Conclusions: Despite the first observation in human experimental malaria infection of a significant association between
vaccine-induced in vitro growth inhibitory activity and in vivo parasite multiplication rate, this did not translate into any
observable clinically relevant vaccine effect in this small group of volunteers.
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Introduction
Recent trends in the incidence of Plasmodium falciparum in several
African countries have returned malaria eradication to the global
health agenda [1]. An effective multi-stage malaria vaccine
combining pre-erythrocytic and blood-stage components would
significantly contribute towards eradication [2], whilst maintaining
blood-stage immunity which could protectagainst epidemic malaria
once natural immunity waned in vaccinated populations. However,
despite considerable efforts, no blood stage vaccine has demon-
strated clinical protection in a field trial to date (reviewed in [3,4]).
Antibodies from malaria-immune individuals and vaccine
recipients can inhibit parasite growth and invasion of erythrocytes
in vitro, as assessed by the standardised assay of growth inhibitory
activity (GIA) [5]. Assays of GIA are regarded as surrogates for
candidate vaccine efficacy and are used for the down-selection of
blood-stage vaccine candidates [3]. However, there are conflicting
data regarding the clinical relevance of assays of GIA (reviewed in
[3]), and to our knowledge no study to date has examined the
relationship between in vitro growth inhibitory activity of vaccine-
induced antibody and in vivo parasite growth rates in humans.
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teers by mosquito bites (sporozoite challenge) or inoculation of
blood-stage parasites (blood-stage challenge) provide direct
evidence of candidate vaccine efficacy before progression to field
trials [6]. Since the number of parasites in the infecting inoculum
can be calculated after administration, blood-stage challenge
allows modeling of parasite multiplication rate (PMR) for
individuals [7] or groups [8] with greater accuracy [9], providing
greater power to detect partial efficacy of blood-stage vaccines
[9,10]. In addition the lower starting blood-stage inocula following
blood-stage challenge results in a prolonged period of sub-patent
parasitaemia during which protective vaccine-induced immune
responses can operate. However just thirty-one humans have been
enrolled in four blood-stage challenge studies to date [9,10,11,12].
Only one was a vaccine efficacy trial, in which no relationship was
observed between PMR and the modest vaccine-induced antibody
and T cell responses; GIA was not measured [11].
Apical membrane antigen-1 (AMA1) is a leading blood-stage
vaccine candidate antigen [3,4]. The recombinant protein vaccine
AMA1-C1 is a combination of the 3D7 and FVO alleles of P.
falciparum AMA1 [13]. AMA1-C1 adsorbed on Alhydrogel was
safe and immunogenic in phase I trials [14,15,16] but demon-
strated no protective efficacy in a phase IIb trial in children in Mali
[17]. Combining AMA1-C1/Alhydrogel with the novel oligodeox-
ynucleotide adjuvant CPG 7909 enhanced immunogenicity in
phase I trials in adults in the US [13,18,19] and Mali [20] and
induced GIA of up to 96%. Here we report the first phase IIa
efficacy trial of AMA1-C1/Alhydrogel+CPG 7909.
Methods
Objectives
The primary objective was to assess the relationship, if any,
between in vitro parasite growth inhibition and parasite multipli-
cation rate in vivo. The secondary objective was to attempt to
detect differences in the parasite multiplication rates between the
vaccinated and unvaccinated subjects. Tertiary objectives were to
obtain further immunogenicity and safety data on AMA1-C1/
Alhydrogel+CPG 7909 in healthy malaria-naı ¨ve adults.
Study Design
This was a phase I/IIa open-label blood-stage malaria vaccine
and challenge trial, including a control group of unvaccinated
volunteers as infectivity controls. Allocation to study groups
occurred at screening based on volunteer preference, as previously
described [21,22,23]. The vaccine recipients received a single
intramuscular dose of the experimental vaccine AMA1-C1/
Alhydrogel+CPG 7909 on days 0 and 56, and underwent
intravenous blood-stage 3D7-strain P.falciparum challenge 14 days
after the second immunisation (on day 70). Control volunteers
underwent simultaneous intravenous blood-stage challenge. Twice
daily P.falciparum quantitative polymerase chain reaction (qPCR)
samples obtained from all challenged volunteers during the
intensive post-challenge follow-up period were used to estimate
parasite multiplication rates per 48 hours for individual volunteers,
using a published mathematical model [7]. These individual
PMRs were compared to results of the in vitro assay of parasite
growth inhibitory activity (GIA) of purified IgG obtained from
individual volunteers on the day of challenge (day 70), to address
the primary study outcome described above.
Participants
The clinical trial protocol and supporting CONSORT checklist
are available as Supplementary Information; see Protocol S1 and
Checklist S1. The study was conducted between July 2009 and
September 2010 at the Centre for Clinical Vaccinology and
Tropical Medicine, University of Oxford, Oxford, UK. Screening
began in July 2009, and the first volunteers were enrolled in
January 2010. Healthy, malaria-naı ¨ve males and non-pregnant
females aged 18–50 were invited to participate in the study.
Inclusion and exclusion criteria for participation have been
previously described [9,23]. As the donor of the parasite inocula
was seropositive for Epstein-Barr virus (EBV) and cytomegalovirus
(CMV), EBV and CMV seropositivity was included as an inclusion
criterion. Due to the potential risk of inducing autoimmunity with
CPG, volunteers were also screened for anti-double stranded DNA
antibodies (ds-DNA) [13]. Urine pregnancy testing of female
volunteers was performed at screening, and prior to vaccination,
challenge and administration of malaria treatment.
Interventions
Vaccinated volunteers were immunised intramuscularly with
AMA1-C1 (80 mg)/Alhydrogel (800 mg), mixed immediately prior
to administration with 564 mg CPG 7909 formulated in saline
(total volume of 0.55 ml), in alternate upper arms on days 0 and
56. Details of the manufacture and formulation of both AMA1-
C1/Alhydrogel and CPG 7909 in saline, and the mixing
procedure used in the clinic have been described in detail
elsewhere [13,24]. Briefly, the AMA1-C1 vaccine contains two
533 amino acid recombinant malaria proteins based on the AMA1
sequences of the FVO and 3D7 clones of P. falciparum. The
recombinant proteins consist of the correctly folded ectodomain
portions of the antigens, with the addition of a six-histidine C-
terminal tag to enable protein purification, and are expressed
separately in Pichia pastoris.
Vaccinated volunteers underwent challenge two weeks after
final immunisation (day 70) together with unvaccinated control
volunteers, by intravenous injection of approximately 1000
erythrocytes infected with 3D7-strain P. falciparum parasites.
Details of the inocula preparation and administration are
described below.
Preparation of Inocula. The origin of the blood-stage
inoculum has previously been described in detail [10]. All
volunteers were challenged with the same preparation of
inocula. The intended inoculum was 1000 infected erythrocytes
per volunteer, thawed and prepared under strict aseptic
conditions. Briefly, a single vial of cryopreserved erythrocytes
was thawed in a containment level III laboratory using solutions
licensed for clinical use and single-use disposable consumables. A
class II microbiological safety cabinet (MSC) that had not
previously been used for pathogen work was used to prepare the
inocula. The MSC was fumigated with formaldehyde prior to use
and no contamination of the hoods was detected by settle plates.
Two hundred microliters of 12% saline was added dropwise to
1 ml of thawed infected blood, left for 5 min, and an additional
10 ml of 1.6% saline added dropwise. This was centrifuged for
4 minutes at 8306g, the supernatant was removed, and 10 ml of
0.9% saline was added dropwise. The cell pellet was washed twice
in 0.9% saline and resuspended in 0.9% saline in a sterile syringe
for injection. The injection volume per volunteer was 5 ml
containing an estimated 1000 parasitised erythrocytes based on
microscopic estimates of the donor’s parasite density prior to
freezing. The clinical inoculum was also cultured following
preparation to exclude bacterial contamination. Alternating
between vaccinees and controls, all subjects were inoculated
intravenously within 40 minutes of inocula preparation to
maximise standardisation of the infecting dose between vaccinees
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the syringe [11].
Inoculum Viability. Parasite viability was assayed by
limiting dilution assay, similar to that described previously [9].
The culture period was shortened to 6 days. Quantitative PCR
was used to score wells positive or negative for replicating
parasites. Because the qPCR assay could also detect dead
parasites, a plate of identical dilutions of inocula that had been
frozen without incubation was used as a negative control. Wells
were scored positive only when post-incubation parasite density
was .100-fold higher than the mean of un-incubated wells at the
same inoculum dilution. The number of viable parasites/ml of
inoculum could then be calculated and viability expressed as a
percentage of the pre-freezing microscopy-estimated parasitaemia
calculated using the RBC count/ml of inoculum.
Post-Challenge Follow-Up. Eligibility of subjects to proceed
to challenge was reviewed by the study clinician prior to
inoculation. The post-challenge follow-up procedure was
identical to that previously described for sporozoite challenge
trials, including twice daily clinical assessment of solicited malaria
symptoms, and twice daily venepuncture for thick film microscopy
and qPCR [23], except that follow-up began 24 hours after
inoculation [9]. Severity of clinical malaria symptomatology was
assessed according to a functional scale also used for vaccine safety
assessment (grade 1: minimal impact on daily activity, grade 2:
interferes with daily activity, grade 3: prevents daily activity).
Severity of fever (measured by oral digital thermometer) in
response to malaria infection was also assessed (grade 1: 37.6uC–
38uC; grade 2: .38uC–39uC; grade 3: .39uC).
Treatment was initiated in response to one of the following: the
identification of a single parasite by thick blood film microscopy;
the onset of significant clinical symptoms of malaria (fever
.37.6uC, rigors, moderate or severe myalgia) in the presence of
a positive qPCR but negative blood film; or reaching day 16
without becoming symptomatic or thick film positive. Treatment
was with a standard course of artemether/lumefantrine (or
chloroquine if artemether/lumefantrine was contra-indicated).
Volunteers were followed-up post-treatment to observe adherence
to the treatment regime and to confirm that drug cure was
successful [23]. To confirm there was no transmission of blood-
borne viruses from the blood-stage inocula, challenged subjects
were also re-tested for HIV, HBV and HCV on day 238.
Safety. Vaccine adverse event data was collected throughout
the study. For vaccine safety assessment vaccinated volunteers
recorded their axillary temperature with a digital thermometer at
least every 24 hours post-vaccination or more frequently if they
had febrile symptoms. In addition, volunteers completed a seven-
day symptom diary recording solicited local symptoms (injection
site pain, induration, erythema, warmth and itch) and systemic
symptoms (arthralgia, fatigue, feverishness, headache, malaise,
myalgia, nausea) following immunisation, and any medication
taken in response to these symptoms. Severity of AEs was assessed
according to the functional scale described above except for
injection site erythema and induration (grade 1: .0–#20 mm,
grade 2: .20–#50 mm; grade 3 .50 mm). Laboratory safety
assessment with haematology and biochemistry tests (including
anti-ds DNA) occurred at days 0, 14, 28, 56, 63, 70, 84, 98, 140
and 238. In addition to guided physical examination at each
timepoint, full physical examination was performed on days 28,
56, 70 and 238.
Outcomes
Quantitative PCR. Blood was collected and prepared for
polymerase chain reaction (PCR) as previously described [25].
Quantitative PCR (qPCR) was performed as previously described in
real-time [25] except using a TaqManH probe - 59 FAM-AACAAT-
TGGAGGGCAAG-NFQ-MGB 39 (Applied Biosystems, sequence
supplied by Rob Hermsen, personal communication) and 12.5 ml
Universal PCR Master Mix with 5 ml sample template per reaction
(25 ml final reaction volume, performed in triplicate) on an Applied
Biosystems Step One Plus PCR System with quantification
performed by Applied Biosystems Step One plus software v2.1.
Mean parasite equivalent values below 20 per ml or with only 1
positive replicate (above 20 parasites/ml) of 3 tested were classed as
negative.
Parasite Multiplication Rate Modelling. The in vivo
parasite multiplication rate per 48 hour life-cycle (PMR) was
estimated using a previously described model [7,26] in which a
linear time effect plus a sine-wave function of parasite growth was
appliedtoindividualvolunteer’slog10transformedqPCRdatausing
the equation: log(P)=tm+a+[c6sin(pt+k)], where a=intercept,
m=gradient, c=sine wave amplitude, k=phase shift in sine wave,
and t=time (days) [7,26]. 10
(2 m) represents the 2-day (i.e., 48 hour)
parasite multiplication rate. The model was constrained to the
known starting log10 parasite inoculum (A0) at t=0 as previously
described [9]. These results also hold when fixing a=A0 and k=0,
or a=A02csin(k) (data not shown). 95% confidence intervals (CIs)
were calculated by use of the root mean square of the SE of each
parameter, which were derived by asymptotic approximation [7].
Samples obtained before the first detection of parasites were
excluded from analysis, and undetectable qPCR values occurring
after the first peak of parasitaemia, due to parasite cycling, were
replaced with the lower limit of detection of the assay (20 parasites/
mL), as previously described [7,9]. The model was applied to all
positive qPCR data from individual subjects with $5 positive
data-points [7].
Growth Inhibitory Activity. Clotted blood samples (sera)
were obtained on the day of enrolment (d0) and the day of parasite
challenge (d70) for the assay of GIA. For the control group
volunteers the day of enrolment was the same as the day of
parasite challenge. GIA assays were performed as previously
described [27]. IgG fractions were purified from individual sera
obtained on day 0 and day 70 using protein G columns (Pierce
Inc., Rockford, IL); the eluted fractions were dialyzed against
RPMI 1640 (Life Technologies, Gaithersburg, MD) and
concentrated with centrifugal filter devices (Millipore, Billerica,
MA) to a concentration of 40 mg/ml. The purified IgGs were
preadsorbed with uninfected human O-negative erythrocytes
(25 ml of RBCs per 1 ml of serum sample) for 1 h to remove
any anti-human erythrocyte immunoglobulins. Purified IgGs were
sterilised by filtration through a 0.22-mm filter (Nalge Nunc,
Rochester, NY). The GIA assay was performed on these samples
using human erythrocytes parasitised with late trophozoite and
schizont stages of P. falciparum prepared by Percoll gradient and/or
5% sorbitol treatment, with a final concentration of IgG in the test
well of 10 mg/ml. Parasite growth after 40 h of culture (for 3D7
parasites) and approximately 47 h of culture (for FVO parasites)
was determined by a biochemical assay specific for parasite lactate
dehydrogenase, and the results were determined by the O.D.650.
The assays were performed once with samples tested in triplicate.
As a positive control, rabbit AMA1-C1 IgG was used for each GIA
plate. The negative control was infected RBC without any IgG.
Starting parasitemia was 0.3+/20.1%. Haematocrit was 1%, and
final parasitemia was 2–3% for the negative control after 40 (3D7)
or 47 (FVO) hours of culture. The results of the GIA assay with the
purified IgGs were expressed as percent inhibition calculated as
follows: 1002[(O.D.650 of infected RBCs with tested
IgG2O.D.650 of normal RBCs only)/(O.D.650 of infected RBCs
AMA1 Malaria Blood Stage Challenge Trial
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and FVO strain responses were assayed; only homologous-strain
assay results are presented.
Enzyme-Linked Immunosorbent Assay (ELISA). Sera for
ELISA were obtained on days 0, 7, 14, 28, 56, and 63 (immunised
group only), and days 70, 84, 98, 140 and 238 (both groups).
ELISA was performed according to a standardised protocol which
has been explained in detail previously [28]. Briefly, ELISA was
performed using the clinical-grade AMA1 antigen. Sera were
tested at 1:500, 1:10,000 and 1:100,000 dilutions, and the dilution
which gave an O.D. in the reliable range was used to calculate
antibody titre. The ELISA unit value of a standard was assigned as
the reciprocal of the dilution giving an O.D. 405=1 in a
standardised assay. The absorbance of individual test samples was
converted into ELISA units using a standard curve generated by
serially diluting the standard in the same plate. Then, ELISA units
were converted to mg/ml using a conversion factor, as reported
elsewhere [29]. 3D7 (homologous strain) data to day 140 are
presented.
Enzyme-Linked Inmmunospot (ELIspot). Heparinised
blood was obtained on days 0, 14, 56, 63 (immunised group),
and days 70, 98 and 238 (both groups). Peripheral blood
mononuclear cells (PBMC) were isolated as previously described
[30] and IFNc ELIspots were performed according to an
established protocol, modified to use 2.5610
5 fresh PMBC per
well [30]. The two allelic forms of the AMA-1 antigen (3D7 and
FVO) were separated into nine peptide pools each containing
20mer peptides overlapping by 10 amino acids at a concentration
of 5 mg/ml and assayed in duplicate. Pools 1–3 contained only
3D7-allele peptides, pools 4–6 contained common peptides shared
between both alleles, and pools 7–9 contained only FVO-allele
peptides. Responses were calculated by subtracting background,
and plates were rejected if background responses were greater than
20 spots per well. The total allelic response (i.e. 3D7-AMA1 or
FVO-AMA1) was calculated by summing responses from the
relevant allele-specific and common peptide pools. Responses were
expressed as spot-forming cells (SFC) per 10
6 PBMC. 3D7
(homologous strain) data to day 98 are presented.
Intracellular Cytokine Staining (ICS). PBMCs cryopreserved
on the day of sampling in liquid nitrogen were thawed and incubated
at 37uC overnight in complete RPMI prior to in vitro stimulation.
1610
6 PBMCs/100 mL were added to 96-well round bottom plates,
a n d3 D 7 - A M Aa n dF V O - A M Ap r o t e i np r o d u c e df r o mP. pastoris
were added to cells at a concentration of 10 mg/ml each. After
2 hours, Brefeldin A (Sigma) was added at 10 mg/ml for an additional
4 hours. Cells were surfaced stained with antibodies CD4-PerCP-
Cy5.5 (RPA-T4) and CD8-PE-Cy7 (RPA-T8) (BD Biosciences). To
discriminate live cells from dead, LIVE/DEAD Fixable Violet Dead
Cell Stain Kit (Invitrogen) was used. For intracellular staining, cells
were fixed with BD Cytofix/Cytoperm, washed, and suspended in
Perm/Wash buffer for staining with antibodies CD3-APC-H7 (SK7),
IFN-c-APC (B27), IL-2-PE (MQ1-17H12), and TNF-a-FITC (mAb-
11) according to the manufacture’s protocol (BD Biosciences).
S a m p l e s( 2 0 0 , 0 0 0e v e n t sp e rs a m p l e )w e r ea c q u i r e do naB DL S R
II and analyzed using FlowJo 9.1 (Tree Star) software. Live CD3
+
cells, CD4
+ and CD8
+ cells were gated to determine the frequencies
of cytokine production. Samples from vaccinated volunteers on day 0
and day of challenge were analysed.
Sample size
Sample size calculations for challenge trials must balance the
need for an adequate sample with the need to reduce risk to
volunteers from exposure to malaria. In most blood-stage
challenge studies performed to date group sizes have been in
single figures. This reflects both practical limitations on the
numbers of individuals that can be recruited and challenged, and
ethical constraints on challenging large numbers of volunteers with
vaccines without any prior evidence of efficacy. The primary
endpoint sample size calculation for this study estimated that with
5 control subjects and 12 vaccinated subjects there was greater
than 80% power to demonstrate a correlation coefficient .0.5 if
the true correlation coefficient was 0.7. The study was not
specifically powered to assess the secondary endpoint. Although
the planned sample size included 12 vaccinated volunteers and 5
controls (with a total 6 controls and 15 vaccinated volunteers to
allow for drop-outs), recruitment was halted after interim primary
endpoint analysis on the vaccinated volunteers (unadjusted for
interim monitoring), which demonstrated that the primary
endpoint had been reached after the initial challenge of 5
vaccinated volunteers and 3 controls.
To assess the primary and secondary endpoints, data from all
challenged subjects for which there were adequate data were
analysed. Immunogenicity and vaccine adverse event analysis for
the tertiary endpoint was performed on an intention-to-treat basis
incorporating all volunteers who received one or more doses of
vaccine.
Statistical Methods and Blinding
Allocation to study groups was not randomised but occurred at
screening based on volunteer preference, as previously described
[21,22,23]. Both the clinical and microscopy teams were blinded
to qPCR results during challenge follow-up. Laboratory staff
conducting blood-film microscopy, ELISA, ICS and GIA were
also blinded to volunteer group allocation. Clinical staff could be
unblinded to individual qPCR values if safety concerns arose
during the challenge follow-up, although this was not required.
Statistical Analysis. Data was classified as skewed (ELISA,
ELIspot, qPCR, ICS) or not (GIA, PMR), and the former log-
transformed in Pearson’s correlation coefficient (r). Groups were
summarised by arithmetic (non-skewed or log transformed skewed
data) or geometric means (skewed) with 95% confidence intervals
(CI) or medians with inter-quartile ranges (IQR), and these were
compared by t test (two sample, non-skewed), Mann-Whitney test
(two sample, skewed), or Wilcoxon signed rank test (paired,
skewed). Safety data analysis was mainly descriptive, however the
Fisher’s exact test was calculated to determine the significance of
any difference in the proportions of volunteers with specific
adverse events following the first and second vaccinations. All tests
Figure 1. Participant Flow. Seventy-five volunteers were screened
for participation, and ten volunteers were enrolled. The majority of
prospective volunteers were excluded by EBV or CMV sero-negativity.
Two immunised volunteers withdrew consent before the challenge due
to moving from the study area, one was replaced prior to challenge.
doi:10.1371/journal.pone.0022271.g001
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Release 11.0 and Graph-Pad Prism 5.0.
Exploratory Analysis. Time to positive qPCR or blood film
was assessed using survival methods (Kaplan-Meier, log-rank test).
Ethics
The clinical trial protocol and associated documents were
approved by the Oxfordshire Research Ethics Committee
(OXREC 07/H0604/137) as well as the National Institute of
Allergy and Infectious Diseases (NIAID) Institutional Review
Board (IRB Protocol No. 08-I-N057). Clinical Trial Authorisation
was granted by the United Kingdom Medicines and Healthcare
Products Regulatory Agency (MHRA 2007-005389-11). All
participants gave written informed consent prior to any study
procedure being undertaken. The study was conducted according
to the principles of the Declaration of Helsinki (2008) and the
International Conference on Harmonisation (ICH) Good Clinical
Practice (GCP) guidelines. The Local Safety Committee provided
safety oversight and GCP compliance was independently moni-
tored by an external organisation (Appledown Ltd, UK).
Results
Participant Flow
Participant flow is summarised in Figure 1. Seventy-five
potential participants were screened for inclusion. Fifty-four
volunteers did not meet inclusion criteria; 52 of these had negative
IgG antibody to either EBV or CMV. Six volunteers were
vaccinated initially. One volunteer withdrew consent after the first
vaccination after moving out of the study area, and was replaced.
This replacement volunteer (V5) therefore received both vaccines
with a four-week interval, whilst other volunteers received two
vaccines with an eight-week interval. Both intervals were
immunogenic in previous phase I trials [13], and this represented
the only deviation from the study protocol during the study.
Another vaccinated volunteer withdrew from the study prior to the
challenge, again because they left the study area. Details of the
vaccine regimens received by all volunteers are included in
Supplementary Table S1.
In total five vaccinated volunteers were challenged together with
three unvaccinated control volunteers.
Recruitment
Recruitment began in July 2009 and continued until March
2010. The first volunteers were vaccinated in January 2010 and
the challenge occurred in April 2010. The final study visits
occurred in September 2010.
Baseline data
The baseline demographic details of the participants in the
vaccine and control groups are included in Table 1. The groups
were similar in distribution for both age (vaccinees median 28
(range: 22–45), controls median 27 (range 25–29) and gender
(male: female ratio in vaccinees 4: 3; controls 1: 2). Inoculum
viability was 25% of the pre-freeze parasitemia, therefore the
actual inoculum delivered was 250 viable parasites per volunteer.
Table 1. Volunteer Demographics.
Characteristics Vaccine Group (n=7) Control Group (n=3)
Male (%)
* 4 (57) 1 (33)
Median age (range)
{ 28 (22–45) 27 (25–29)
Median time to inoculation in minutes (IQR)
{m 4 (0.5–7.5) 4 (0–4)
No significant differences were identified between the groups using
*Fisher’s exact test (P=1.0) and
{Mann-Whitney test (P=0.83).
mApplies only to the 5/7 vaccinated volunteers who underwent challenge. IQR=interquartile range.
doi:10.1371/journal.pone.0022271.t001
Figure 2. Vaccine-Induced in vitro Growth Inhibitory Activity (GIA) and Antibody Titre Correlates with in vivo Parasite Multiplication
Rate (PMR). (N) Represents immunised volunteers and (#) represents control volunteers. All analyses are two-tailed Pearson correlation coefficients.
Assays of GIA and ELISA (both 3D7-AMA1) were performed once in triplicate on day of challenge samples. GIA is expressed as percent inhibition
calculated as follows: 1002[(O.D.650 of infected RBCs with tested IgG2O.D.650 of normal RBCs only)/(O.D.650 of infected RBCs without any
IgG2O.D.650 of normal RBCs only)6100]. ELISA units are log10 mg/ml. Parasite multiplication rate per 48 hours was modelled from qPCR data. A.
Correlation between vaccine-induced GIA on day of challenge and 48-hour PMR (r=20.93 [95% CI: 21.0, 20.27] P=0.02). When all volunteers
(vaccinated and control) were examined together there was a trend towards an association (r=20.61 [95% CI: 20.94, 0.27] P=0.15). B. Correlation
between log10 transformed 3D7-AMA1 ELISA (mg/ml) and 48-hour PMR (r=20.93 [95% CI: 20.99, 20.25] P=0.02).
doi:10.1371/journal.pone.0022271.g002
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Only three positive qPCR data points were available for one
control volunteer (C1), insufficient for accurate estimation of PMR
for this individual. This volunteer is therefore excluded from
primary and secondary outcome analysis. There was a significant
inverse correlation between PMR and homologous-strain (3D7)
GIA on day of challenge (day 70) in the vaccine recipients
(r=20.93 [95% CI: 21.0, 20.27] P=0.02, Figure 2A). This was
also observed for log10 ELISA against homologous-strain (3D7)
AMA1 on day of challenge (day 70) (r=20.93 [95% CI: 21.0,
20.25] P=0.02, Figure 2B). When immunised and control
volunteers were analysed together the GIA correlation became
non-significant (r=20.61 [95% CI: 20.94, 0.27] P=0.15,
Figure 2A). No correlation was observed with PMR and
heterologous-strain (FVO) GIA and log10 ELISA responses (data
not shown).
Secondary Outcome
Assessment of secondary outcome was limited by having only
two control volunteers in which PMR could be accurately
modelled. No significant difference was observed in mean PMR
between the vaccine and control groups (vaccine group 16-fold
[95% CI: 12–22], control group 17-fold [95% CI: 0–65], P=0.70
t test, Figure 3A). The parasite multiplication rates in 48 hours
(with 95% CIs) for individual vaccinated volunteers were: V1: 17.8
fold (13.6–23.3); V2: 17.5 fold (11.1–27.6); V3: 15.7 fold (12.5–
19.8); V4: 10.3 fold (10.1–10.4); V5: 20.0 fold (16.7–23.9). For
individual control volunteers the PMR was C2: 13.9 fold (11.0–
17.6), and C3: 21.4 fold (17.1–26.8), Figure 3A. The modelling
strategy fitted the data well. The mean R
2 value was 0.93 for
vaccinated subjects and 0.92 for controls with a mean of 6.6 PCR
data points per volunteer. Raw qPCR data are summarised in
Supplementary Table S2.
Tertiary Outcomes
Antibody Immunogenicity. On the day of challenge, mean
percentage vaccine-induced GIA was significantly greater in the
vaccine group (63% [95% CI: 38–90]) than the control group
(13% [95% CI: 9–19] P,0.01, t test Figure 3B). GIA was
maintained but not boosted at 28 days post-challenge (61% [95%
CI: 17–100]), and did not increase significantly post-challenge in
the control group (data not shown).
A significant increase in geometric mean 3D7-strain antibody
response measured by ELISA (mg/mL) was observed after the first
immunisation (n=7) (d28: 8.3 mg/mL [95% CI: 4.0–17.5] vs d0:
1.27 mg/mL [range 1.27–1.27], P=0.02 Wilcoxon signed rank
test, Figure 4A). Responses were non-significantly boosted by the
second immunisation in challenged volunteers (n=5) (d63:
117.4 mg/mL [95% CI: 58.9–233.9] vs d28, P=0.06 Wilcoxon
signed rank test, Figure 4A), and were maintained but not boosted
by challenge. ELISA titre was significantly higher in vaccinated
volunteers at day of challenge (geometric mean vaccine group
Figure 3. Individual Subject Parasite Multiplication Rates and
Immunological Measures at Day of Challenge. (N) Represents
immunised volunteers and (#) represents control volunteers. All panels
display means and error bars represent 95% confidence intervals.
Assays of GIA and ELISA were performed once in triplicate. ELIspot
assays were performed once in duplicate. GIA is expressed as percent
inhibition calculated as follows: 1002[(O.D.650 of infected RBCs with
tested IgG2O.D.650 of normal RBCs only)/(O.D.650 of infected RBCs
without any IgG2O.D.650 of normal RBCs only)6100]. ELISA units are
mg/ml, ELIspot units are IFN-c spot forming colonies (SFCs) per 10
6
PBMCs. Parasite multiplication rate per 48-hours was modelled from
qPCR data. A. 48-hour parasite multiplication rates (PMR) for individuals
and arithmetic mean 48-hour PMR for the group. PMR for volunteer C1
could not be accurately modelled as there were only three qPCR data-
points [7]. Arithmetic mean PMRs were not significantly different
(vaccine 16-fold [95% CI: 12–22] (n=5), control 17-fold [95% CI: 0–65]
(n=2) P=0.70, t test). B. Individual and group mean percentage GIA.
There were similar levels of detectable GIA in all volunteers at
enrollment (d0 for immunised group, day of challenge for control
group); mean vaccine group 21% [95% CI: 13–30] (n=5), control group
13% [95% CI: 8–19] (n=3) P=0.10, t test. C. Geometric mean antibody
ELISA (mg/ml) and D. geometric mean T cell ELIspot responses (IFN-c
SFC/10
6 PMBC) to 3D7-AMA1 at day 0 (immunised group) and day of
challenge (all groups, the first assessment for controls was day of
challenge). All immunology endpoints were significantly higher in
vaccinees than controls at challenge (GIA P,0.01 t test; ELIspot P=0.04
Mann-Whitney; ELISA P=0.04 Mann-Whitney).
doi:10.1371/journal.pone.0022271.g003
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CI: 0.8–2.8] P=0.04, Mann-Whitney test, Figure 3C). No
significant increase in ELISA titre was identified in the control
volunteers (n=3) post-challenge.
As we have previously observed, 3D7 GIA and 3D7 log10
ELISA titres correlated strongly (r=0.97, P,0.01), as did 3D7
and FVO log10 ELISA titres (r=0.90, P=0.03) [13].
Cellular Immunogenicity. A significant increase in
geometric mean T cell response measured by ex vivo IFN-c
ELIspot (spot-forming colonies (SFC) per 10
6 PBMCs) was
observed following the first immunisation in all volunteers (n=7)
(d14: 197.8 IFN-c SFC/10
6 PBMCs [95% CI: 94.2–415.7]) vs d0:
30.1 IFN-c SFC/10
6 PBMCs [95% CI: 14.3–62.0], P=0.02
Wilcoxon signed rank test, Figure 4B). These responses contracted
non-significantly by day 56 after the first immunisation (geometric
mean 63.6 IFNc SFC/10
6 PBMCs [95% CI: 27.3–147.9];
P=0.06, Wilcoxon signed-rank test), and were non-significantly
boosted by the second immunisation in challenged volunteers
(n=5) (d70 geometric mean 282.4 IFN-c SFC/10
6 PBMCs [95%
CI: 113.3–704.3] P=0.06 Wilcoxon signed rank test, Figure 4B).
T cell responses by ELIspot were significantly higher in vaccinated
volunteers at day of challenge (geometric mean vaccine group
282.4 IFN-c SFC/10
6 PBMCs [95% CI: 113.3–704.3], control
group 20.9 IFN-c SFC/10
6 PBMCs [95% CI: 8.0–38.0] P=0.04,
Mann-Whitney test, Figure 3D). No significant increase in
detectable response was observed in control volunteers post-
challenge, Figure 4B.
The phenotype of the vaccine-induced T cell responses was
predominantly CD4
+ by flow cytometry (data not shown). On the
dayofchallenge(dCH)AMA1-C1antigen-stimulatedTh1responses
weredetectedinallvaccinatedvolunteers(n=5) andmultifunctional
responses were detected. There was a non-significant trend to an
increase in the frequency of live CD3
+ CD4
+ T cells positive for
TNF-a,I F N - c and IL-2 after vaccination (TNF-a d0: 0.003%
[range 0.002–0.014], dCH: 0.009% [range 0.0–0.035], P=0.31;
IFN-c d0: 0.0% [range 0.0–0.020], dCH: 0.010% [0.0–0.069],
P=0.58; IL-2 d0: 0.036% [range 0.022–0.061], dCH: 0.051%
[range 0.035–0.072], P=0.13 Wilcoxon signed rank test, Figure 5).
There was no significant correlation between T cell responses on the
day of challenge, measured by either ELIspot or ICS, and in vivo
parasite multiplication (data not shown).
Adverse Events
Nounexpected or seriousadverse events(AEs) occurred.Vaccine-
related AEs occurred at a similar frequency following both
vaccinations (Supplementary Table S3). The majority of AEs were
grade 1 in severity (Figure 6). Overall, the median duration of all
injection-siteAEswas3days(IQR:2–3.75).Therewasnosignificant
difference in the duration of local or systemic AEs between the first
or second doses (local P=0.14; systemic P=0.12, Mann Whitney
test). The only vaccine-related laboratory abnormality was transient
grade 1 leucopenia in a single subject following the first vaccination,
which is expected with CPG 7909 [13]. Double-stranded DNA
antibodies were not observed in any volunteers.
Ancillary analyses
Challenge Endpoints. All volunteers were inoculated within
40 minutes of inocula preparation. All volunteers developed
microscopy positive parasitaemia on thick-film by day 9 post-
challenge (range 7–9). Although not surprising for a small sample,
there was no significant difference in pre-patent period between
the vaccine and control groups by survival analysis (vaccine group
median 8.5 days (range 7.5–9), control group median 9 days (range
7–9) P=0.45 log-rank test, see Figure 7A). There was also no
significant difference in days to first positive PCR between the
vaccine and control groups by survival analysis (vaccine group
median 5.5 days (range 5–5.5), control group median 5.5 days
(range 5–6.5) P=0.40 log-rank test, see Figure 7B). Individual
volunteer qPCR values are displayed in Figure 8A (vaccine group)
and Figure 8B (control group). Parasite density at diagnosis
(vaccine group median 4602 p/ml [IQR: 1472–19632], control
group median 3613 p/ml [IQR: 543–11402]) was not significantly
different (P=0.79 Mann-Whitney test, Figure 8C). Only 2/8
volunteers developed a malaria symptom (grade 1 myalgia in 2/8,
feverishness in 1/8) at the time of blood-film diagnosis. After
treatment initiation six volunteers developed minor grade 1
malaria symptoms. None had objective fever. There were no
challenge-related laboratory abnormalities.
Discussion
We observed a significant inverse relationship between vaccine-
induced GIA and parasite multiplication rate in vaccinated
Figure 4. Timecourse of Homologous (3D7) Strain Antibody and T Cell Responses. (N) Represents immunised volunteers and (#)
represents control volunteers. Numbers on ‘x’ axes represent days of follow-up. Arrows represent immunisations. Geometric mean 3D7-strain AMA1
antibody responses by ELISA (mg/ml) (A) and ex vivo 3D7-strain IFN-c ELIspot (SFC/10
6 PMBC) (B) for immunised volunteers (n=7) and controls (n=3)
are presented. ELISA assays were performed once in triplicate. ELIspot assays were performed once in duplicate. Statistical comparisons are with the
two-tailed Wilcoxon signed rank test. A. A significant increase in 3D7-strain AMA1 antibody responses by ELISA (mg/ml) was observed for first
immunisation (n=7). Responses were non-significantly boosted by the second immunisation in challenged volunteers (n=5) and were maintained at
day 140. No significant increase in detectable response was identified in the control volunteers post-challenge. B. A significant increase in ex vivo
3D7-strain IFN-c ELIspot (SFC/10
6 PMBC) response was observed following the first immunisation in all volunteers (n=7). Responses were non-
significantly boosted by the second immunisation in challenged volunteers (n=5). No significant increase in detectable response was observed in
control volunteers post-challenge.
doi:10.1371/journal.pone.0022271.g004
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needs to be confirmed in larger studies. However, there was no
evidence to suggest that the magnitude of the vaccine-induced
effect was sufficient to impact overall PMR in the vaccinated
volunteers, and there was consequently no effect on pre-patent
period. However the small sample size, particularly that of the
control group, limited the statistical power to assess differences in
PMR between the groups.
GIA induced in most vaccinated volunteers may have been
insufficient to significantly reduce PMR in comparison to
unvaccinated controls. Although the volunteer with 90% in vitro
growth-inhibitory activity had the lowest parasite multiplication
rate (10-fold), in most volunteers the GIA did not reach this level.
Other adjuvanted AMA1 vaccines have induced similar levels of
GIA without a significant impact on estimated PMR, albeit after
sporozoite challenge [31]. Modelled estimates suggest much
greater antibody levels are required to control in vivo parasite
growth [8]. Non-human primate studies have shown that very
high antibody titers and in vitro growth inhibition of .70% (using
Figure 5. Intracellular Cytokine Staining. AMA1-C1 protein-
stimulated live CD3
+ CD4
+ T cells positive for the Th1 cytokines IFN-c
TNF-a and IL-2 assayed on cryopreserved PBMCs obtained on the day of
enrollment (d0) and day of challenge (dCH) from vaccinated and
challenged volunteers (n=5). Statistical comparisons are with the two-
tailed Wilcoxon signed rank test. There was a non-significant increase in
median percentage of live CD3
+ CD4
+ cells positive for TNF-a, IFN-c and
IL-2 (TNF-a d0: 0.003% [range 0.002–0.014], dCH: 0.009% [range 0.0–
0.035], P=0.31; IFN-c d0: 0.0% [range 0.0–0.020], dCH: 0.010% [0.0–
0.069], P=0.58; IL-2 d0: 0.036% [range 0.022–0.061], dCH: 0.051% [range
0.035–0.072], P=0.13 Wilcoxon signed rank test).
doi:10.1371/journal.pone.0022271.g005
Figure 6. Adverse Events. All solicited and unsolicited adverse
events post-vaccination considered possibly, probably or definitely
vaccine-related up to day 140. One volunteer experienced a grade 3
headache and rigors on the evening of the first dose (day 0) which
required oral analgesia and resulted in a missed day of work. The rigors
resolved within several hours and the headache reduced in intensity
within 24 hours, and resolved on day 2. ‘Other’ refers to transient
injection-site discomfort relating to minor trauma 5 days after
vaccination.
doi:10.1371/journal.pone.0022271.g006
Figure 7. Kaplan-Meier Survival Analysis of Time to Parasitaemia. Survival analysis of A. time to parasitaemia by thick blood film microscopy
(P=0.45 log-rank test), vaccine group (bold line) median 8.5 days (range 7.5–9), control group median 9 days (range 7–9) B. Time to first positive
qPCR value (P=0.40 log-rank test), vaccine group median 5.5 days (range 5–5.5), control group median 5.5 days (range 5–6.5).
doi:10.1371/journal.pone.0022271.g007
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[32]. Similar results in primates have been reported for another
blood-stage antigen, MSP1 [33]. A recent study indicates the pre-
patent PMR in semi-immune Gambian adults is significantly lower
than has ever been achieved by a blood-stage vaccine candidate in
humans [34].
As well as antibodies [35], other immune responses are likely to
be involved in determiningin vivo PMR, including, cytokines [36], T
effector [12] and T regulatory cells [36] and antibody-dependent
cellular inhibition (ADCI) by monocytes [37,38] and neutrophils
[39]. We observed a clear relationship between homologous-strain
log10 ELISA titre and PMR in vaccinees but there was no
relationship between PMR and the modest vaccine-induced CD4
+
T cell responses measured by ex-vivo IFN-c ELIspot or ICS. This
may reflect the insufficient magnitude of the T cell response, lack of
statistical power to detect such a relationship, analysis of the non-
protective T cell phenotype, or the absence of an association.
The association between GIA and PMR in vaccinees reported
in this study provides some support for a protective role of very
high levels of GIA-inducing antibodies, but this result need not
imply causation. A recent meta-analysis of prospective sero-
epidemiological studies demonstrated an association between IgG
to merozoite proteins and reduced clinical malaria [35]. Fewer
studies have prospectively assessed functional antibody responses
such as GIA [3,35]. Most of these studies suggest that antibody
demonstrating inhibitory activity in vitro contributes to a reduced
risk of clinical malaria [5,40,41], although some do not [42]
(reviewed in [3]). The data are similarly conflicting in numerous
animal models [32,33,43], suggesting that multiple potential
immune effector mechanisms may operate in humans (reviewed
in [3]). Data from a sporozoite challenge trial of an AMA1-
containing multi-stage virosomal vaccine demonstrated significant
reduction in PMR without detectable GIA or cellular responses
[23]. However, there was also a trend to reduced liver-emerging
parasites. A similar significant reduction in liver-emerging
parasites was observed with the adjuvanted AMA1 vaccine
discussed above [31], which may have also induced strain-specific
efficacy in a field trial in Malian children [Ouattara A., Takala-
Harrison S. et al. Allele-Specific Efficacy of the Monovalent Apical
Membrane Antigen 1 (AMA1) Malaria Vaccine FMP2.1/AS02A,
American Society of Tropical Medicine and Hygiene, November
2010, Abstract #803]. In these studies it is therefore difficult to
rule-out the possibility that PMR could have been influenced by
immune responses to sporozoites, liver-stage parasites or liver-
emerging merozoites, all of which express AMA1 [31]. An
inherent limitation of the blood-stage challenge model is thus an
inability to detect any pre-erythrocytic vaccine efficacy. Another
limitation specific to this inoculum is the requirement for volunteer
EBV and CMV seropositivity, which adversely impacted recruit-
ment in this study.
There was an unexpectedly low frequency of clinical malaria
symptoms pre-diagnosis (2/8 subjects) inthis study incomparison to
published data on the clinical features of experimental malaria in
healthy volunteers following sporozoite challenge [44]. Parasite
density at microscopic diagnosis (geometric-mean 4012 p/ml) was
similar to that recorded in sporozoite-challenged control volunteers
inarecentstudy(geometric-mean4030p/ml),10/12ofwhomwere
symptomatic at diagnosis [Ewer K, O’Hara GA, Duncan CJA et al.,
submitted], suggesting potential attenuated pathogenicity of the
blood-stage challenge parasites. Differential expression and rate of
switching of expressed var genes by parasites in this inoculum after
blood-stage passage has been reported, which could explain the
reduction in clinical symptoms observed [45].
This is the first trial in humans to explore the relationship
between vaccine-induced inhibitory antibodies and in vivo parasite
growth rates following experimental blood-stage malaria infection.
It increases by more than a quarter the total number of volunteers
who have been experimentally infected with this inoculum, and is
only the second vaccine efficacy study using this model. As the first
Phase IIa challenge trial of AMA1-C1/Alhydrogel+CPG 7909, it
contributes further safety and immunogenicity data on this
protein-adjuvant combination. However, there is insufficient
evidence to support future phase IIb clinical trials of this vaccine
formulation in the immunisation regimen assessed here. While the
blood-stage challenge model has limitations, the use of challenge
studies (both blood-stage and sporozoite) should greatly speed the
clinical development of blood-stage vaccines, allowing early
demonstration of possible benefit and rational down-selection of
vaccine candidates prior to field trials.
Supporting Information
Table S1 Vaccine Regimens. V5 was immunised to replace
V6 who withdrew from the study on day 28. V5 therefore received
two immunisations 28 days apart, but this dose interval did not
impact on vaccine immunogenicity [since fold-increase in ELISA
titre (mg/mL) following the second immunisation for V5 was
similar to V1–V4 (data not shown)]. Volunteers V1–V5 were
challenged simultaneously 14 days after the final immunisation.
(DOC)
Table S2 Raw qPCR Dataset. D=day post-challenge,
V=vaccinated subject, C=control. Bold text=qPCR on day of
blood film diagnosis.
(DOC)
Figure 8. Quantitative PCR. Individual qPCR data (parasites/ml) for A. immunised and B. control volunteers. C. Median qPCR data (with
interquartile ranges) for vaccine and control groups. No significant differences were observed between the groups at any time-point (data not
shown). qPCR was performed once in triplicate at each time-point.
doi:10.1371/journal.pone.0022271.g008
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Post-Vaccination with AMA1-C1/Alhydrogel+CPG 7909.
The maximum severity of any AE experienced by the volunteer is
recorded. Overall percentage of AEs experienced by volunteers
after either dose is summarised in final column. Some AEs were
reported by the same volunteer after both immunisations.
*Both
grade 3 systemic AEs occurred simultaneously in the same
volunteer.
{Recurrent minor transient discomfort at injection-site
day 5 following dose 1. No significant differences in proportion of
volunteers experiencing AEs between dose 1 and dose 2 were
identified by Fisher’s exact test.
(DOC)
Protocol S1 Trial Protocol.
(PDF)
Checklist S1 CONSORT Checklist.
(DOC)
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